Literature DB >> 11588178

Induction of alpha-synuclein aggregation by intracellular nitrative insult.

E Paxinou1, Q Chen, M Weisse, B I Giasson, E H Norris, S M Rueter, J Q Trojanowski, V M Lee, H Ischiropoulos.   

Abstract

Brain lesions containing filamentous and aggregated alpha-synuclein are hallmarks of neurodegenerative synucleinopathies. Oxidative stress has been implicated in the formation of these lesions. Using HEK 293 cells stably transfected with wild-type and mutant alpha-synuclein, we demonstrated that intracellular generation of nitrating agents results in the formation of alpha-synuclein aggregates. Cells were exposed simultaneously to nitric oxide- and superoxide-generating compounds, and the intracellular formation of peroxynitrite was demonstrated by monitoring the oxidation of dihydrorhodamine 123 and the nitration of alpha-synuclein. Light microscopy using antibodies against alpha-synuclein and electron microscopy revealed the presence of perinuclear aggregates under conditions in which peroxynitrite was generated but not when cells were exposed to nitric oxide- or superoxide-generating compounds separately. alpha-Synuclein aggregates were observed in 20-30% of cells expressing wild-type or A53T mutant alpha-synuclein and in 5% of cells expressing A30P mutant alpha-synuclein. No evidence of synuclein aggregation was observed in untransfected cells or cells expressing beta-synuclein. In contrast, selective inhibition of the proteasome resulted in the formation of aggregates detected with antibodies to ubiquitin in the majority of the untransfected cells and cells expressing alpha-synuclein. However, alpha-synuclein did not colocalize with these aggregates, indicating that inhibition of the proteasome does not promote alpha-synuclein aggregation. In addition, proteasome inhibition did not alter the steady-state levels of alpha-synuclein, but addition of the lysosomotropic agent ammonium chloride significantly increased the amount of alpha-synuclein, indicating that lysosomes are involved in degradation of alpha-synuclein. Our data indicate that nitrative and oxidative insult may initiate pathogenesis of alpha-synuclein aggregates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588178      PMCID: PMC6763872     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  61 in total

1.  MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.

Authors:  N W Kowall; P Hantraye; E Brouillet; M F Beal; A C McKee; R J Ferrante
Journal:  Neuroreport       Date:  2000-01-17       Impact factor: 1.837

2.  Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice.

Authors:  C Ayata; G Ayata; H Hara; R T Matthews; M F Beal; R J Ferrante; M Endres; A Kim; R H Christie; C Waeber; P L Huang; B T Hyman; M A Moskowitz
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

Authors:  S Przedborski; V Kostic; V Jackson-Lewis; A B Naini; S Simonetti; S Fahn; E Carlson; C J Epstein; J L Cadet
Journal:  J Neurosci       Date:  1992-05       Impact factor: 6.167

4.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.

Authors:  J M Souza; B I Giasson; Q Chen; V M Lee; H Ischiropoulos
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

5.  Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Authors:  S Przedborski; Q Chen; M Vila; B I Giasson; R Djaldatti; S Vukosavic; J M Souza; V Jackson-Lewis; V M Lee; H Ischiropoulos
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

6.  Cysteine proteinase inhibitors and ras gene products share the same biological activities including transforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells.

Authors:  T Hiwasa; T Sawada; S Sakiyama
Journal:  Carcinogenesis       Date:  1990-01       Impact factor: 4.944

7.  Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.

Authors:  M Lee; D Hyun; B Halliwell; P Jenner
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

8.  Widespread peroxynitrite-mediated damage in Alzheimer's disease.

Authors:  M A Smith; P L Richey Harris; L M Sayre; J S Beckman; G Perry
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

9.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Authors:  S Przedborski; V Jackson-Lewis; R Yokoyama; T Shibata; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation.

Authors:  K Hensley; M L Maidt; Z Yu; H Sang; W R Markesbery; R A Floyd
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

View more
  136 in total

Review 1.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association?

Authors:  Harry Ischiropoulos; Joseph S Beckman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 2.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

3.  Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Authors:  Joseph Rasimas; Antonios Katsounas; Haniya Raza; Alison A Murphy; Jun Yang; Richard A Lempicki; Anu Osinusi; Henry Masur; Michael Polis; Shyam Kottilil; Donald Rosenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

Review 4.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

5.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 6.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

7.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Authors:  Lee J Martin; Yan Pan; Ann C Price; Wanda Sterling; Neal G Copeland; Nancy A Jenkins; Donald L Price; Michael K Lee
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

8.  Site-specific differences in proteasome-dependent degradation of monoubiquitinated α-synuclein.

Authors:  Tharindumala Abeywardana; Yu Hsuan Lin; Ruth Rott; Simone Engelender; Matthew R Pratt
Journal:  Chem Biol       Date:  2013-10-24

9.  Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets.

Authors:  Ashley D Reynolds; David K Stone; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells.

Authors:  Tereza Vogiatzi; Maria Xilouri; Kostas Vekrellis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.